The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean ...
Each year 29 June marks World Scleroderma Day. This article highlights the symptoms, latest research and a genuine ‘diary’ experience from a US patient. The date 29 June was chosen to raise awareness ...
Substantial evidence exists that patients with scleroderma have immune dysfunction and autoimmunity, and several studies support the use of immunosuppressive treatment in these patients. Nihtyanova et ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback